Novavax, Inc. · NASDAQ:NVAX
Novavax — J.P. Morgan 42nd Annual Healthcare Conference 2024
24 slides from Novavax's conference presentation, Jan 8, 2024
Slide 1: J.P. Morgan 42nd Annual Healthcare Conference
J.P. Morgan 42 nd Annual Healthcare Conference 1 © 2024 NOVAVAX. All rights reserved. NASDAQ: NVAX | JANUARY 2024
Slide 2: Forward-looking statements
This presentation includes forward - looking statements . These forward - looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning . These forward
Slide 3: Introduction
Introduction SE C T I O N 3 © 2024 NOVAVAX. All rights reserved.
Slide 4: "It's just another number" … or is it?
4 © 2024 NOVAVAX. All rights reserved. “It’s just another number” … or is it? 3,000,000 1,300 630,000 Sources: WHO.int, CDC.gov, Ourworldindata.org. 41,000,000 710,000 52,000
Slide 5: 50,000,000 deaths can be prevented through immunization 2021-2030
5 © 2024 NOVAVAX. All rights reserved. 50,000,000 deaths can be prevented through immunization between 2021 - 2030 Est. 150,000,000 – 200,000,000 lives have been saved between 1980 and 2018 from smallpox vaccination alone Sources: CDC.gov, Ourworldindata.org.
Slide 6: Novavax is here to make a difference
6 Novavax is here to make a difference. We’re a biotech company focused solely on developing life - saving vaccines to fight infectious diseases. © 2024 NOVAVAX. All rights reserved. What we do as an industry matters, we have made and will continue to make a positive impact on health for millions of
Slide 7: Company Overview
C o m p a ny Overview SE C T I O N 7 © 2024 NOVAVAX. All rights reserved.
Slide 8: Novavax corporate highlights
Novavax corporate highlights 8 © 2024 NOVAVAX. All rights reserved. Positioned for long - term value creation through commercialization of proven technology Proprietary Matrix - M TM adjuvant differentiates pipeline Rapidly advancing COVID - 19 - Influenza Combination (CIC) vaccine to Phase 3 1 Prov
Slide 9: Fully integrated commercial-stage biotechnology company with global presence
Fully integrated commercial - stage biotechnology company with global presence 9 © 2024 NOVAVAX. All rights reserved. Global HQ & Corporate Offices • R&D and discovery laboratories • Manufacturing operations • Commercial Novavax HQ Novavax HQ Gaithersburg, Maryland Novavax AB Uppsala, Sweden Novavax
Slide 10: Novavax's proven technology platform
Novavax’s proven technology platform 10 © 2024 NOVAVAX. All rights reserved. • Antigen sparing 2 • Large safety database included in approved vaccines 2,3 • Reactogenicity consistent with licensed vaccines 2,3 Matrix - M Adjuvant Technology Performance Characteristics • Induces broad, robust neutral
Slide 11: Novavax's core vaccine pipeline
Novavax’s core vaccine pipeline Significant opportunities for future development 11 © 2024 NOVAVAX. All rights reserved. 1. Authorized in select geographies under trade names Novavax COVID - 19 Vaccine, Adjuvanted; Covovax TM ; and Nuvaxovid. 2. Authorized in the U.S. under trade name Novavax COVID
Slide 12: R21/Matrix-M vaccine against malaria approved
R21/Matrix - M vaccine against malaria approved to help address dire global public health need 12 © 2024 NOVAVAX. All rights reserved. Highly Efficacious Vaccine Demonstrates Promise of Novavax Technology Platform • Formulated with Novavax’s Matrix - M adjuvant 1 • Prequalified by WHO in Dec. 2023;
Slide 13: 2023: A Year in Review
2023: A Year in Review SE C T I O N 13 © 2024 NOVAVAX. All rights reserved.
Slide 14: 2023 was a year of significant change for Novavax
14 © 2024 NOVAVAX. All rights reserved. 2023 was a year of significant change for Novavax with a strong focus on building a robust and sustainable business • Delivered updated vaccine in - line with regulatory authority requirements • Delivered on our APA commitments, gained experience in U.S. marke
Slide 15: Looking Ahead: Significant Future Opportunity for Novavax
Looking Ahead: Significant Future Opportunity for Novavax SE C T I O N 15 © 2024 NOVAVAX. All rights reserved.
Slide 16: Setting the stage for a stronger U.S. commercial performance in 2024+
Setting the stage for a stronger U.S. commercial performance in 2024+ 1. IPSOS syndicated Awareness, Trial and Usage tracker (From March 2023 to September 2023), HCP monthly pulse (starting in October 2023). 2. IQVIA NPA Data and Claims Data. 16 © 2024 NOVAVAX. All rights reserved. 2023 - 2024 Vacci
Slide 17: Significant future U.S. market opportunity for combination respiratory vaccines
0 20 40 60 80 1 0 0 1 2 0 1 4 0 1 6 0 Flu COVID - 19 Millions of doses 2019 - 2022 Average 130M - 140M Significant future U.S. market opportunity expected for combination respiratory vaccines • High unmet need and preference for a combination Flu & COVID - 19 vaccine o Potential for increased COVID
Slide 18: Well-positioned to deliver a differentiated combination vaccine
18 © 2024 NOVAVAX. All rights reserved. Novavax is well - positioned to deliver a differentiated combination vaccine and capture significant market opportunity Leverage Proven Technology Platform 1. Protein Receptivity Study (January 2022). 2. IQVIA Demand Study (2023). 3. IPSOS syndicated Awareness
Slide 19: CIC/Flu Phase 2 study summary observations
CIC/Flu Phase 2 study summary observations 19 © 2024 NOVAVAX. All rights reserved. S t and - a lo ne Influenza Vaccine CIC Vaccine Combines stand - alone influenza vaccine and NVX - CoV 2373 in single injection Matrix - M a d j uv ant + Quadrivalent vaccine with four influenza Hemagglutinin genes Ma
Slide 20: Positioned to support the expansion of our product portfolio
20 © 2024 NOVAVAX. All rights reserved. Novavax is positioned to support the expansion of our product portfolio Product Portfolio Novavax Readiness Posture T oday COVID - 19 Vaccine R21 / M a tr i x - M Malaria Vaccine 1 CIC Vaccine Potential launch in 2026 2 COVID - 19 Vaccine R21 / M a tr i x - M
Slide 21: R&D and SG&A expense guidance for 2023-2024
R&D and SG&A expense guidance for 2023 - 2024 21 © 2024 NOVAVAX. All rights reserved. $1 . 7B $1.15B - $1.25B cost reduction program reshape Novavax business is prepared t o fu r t h er operations beyond previously announced 2024 targets o Executed successfully against previously stated targets for
Slide 22: Summary: Progress and learnings from 2023 create strong foundation 2024+
22 © 2024 NOVAVAX. All rights reserved. Summary: Progress and learnings from 2023 create strong foundation 2024+ • Potential CIC vaccine launch in fall 2026 season 2 • Large market and potential for differentiation as only protein - based option Significant future opportunity for Novavax • Identifie
Slide 23: We never rest in our quest to protect the health of people everywhere
23 © 2024 NOVAVAX. All rights reserved. We never rest in our quest to protect the health of people everywhere.
Slide 24: Q&A
Q&A 24 © 2024 NOVAVAX. All rights reserved.
Novavax — J.P. Morgan 42nd Annual Healthcare Conference 2024 on 6ix